Rett Syndrome Health Checklist

The Rett Syndrome Health Checklist, published by the Rett Disorders Alliance UK (Reverse Rett, Rett UK and FOXG1).

The Rett syndrome Health Checklist provides information to help with symptom identification and management, including suggestions for drugs which may help and those which may cause difficulties for people with Rett syndrome. There are also links to relevant research papers, case studies, and best practice guidance.

Many thanks to everyone who has contributed to this important document and to The Bolland Charitable Fund for their support.

The checklist was developed through two years of collaborative work between Reverse Rett, Rett UK, FOXG1 UK  and the UK Rett Disorders Working Group. This consists of clinicians, therapists, consultants and experts by experience such as families, caregivers and patient organisations representing them.

 

We hope you will find this a key ‘go to’ document to advocate for the best care and treatment for your daughter or son.

Please share it with key people involved in their care.

 

Request yours now

If you would like a copy of the Rett Syndrome Health Checklist, please fill out the form below and we will send one in due 7-10 working days. Any enquiries, please email [email protected]

    Your Details

     

    Contact Details

    Latest news

    • Update from Taysha Gene Therapies

      Update from Taysha Gene Therapies

        Taysha Gene Therapies have provided an update on their Rett syndrome clinical trials
    • Join Our Mission: Senior Development Officer Role at Reverse Rett

      Join Our Mission: Senior Development Officer Role at Reverse Rett

      We are seeking an experienced Senior Development Officer to join Reverse Rett to help
    • Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

      Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

      On June 18th, Neurogene provided an update on the first “high dose” patient in